Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

P21 vs Dihexa

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

The short answer

Verdict: favors P21

Neither P21 nor dihexa has ever been tested in people, neither has a lawful US source, and both are prohibited in sport as non-approved substances. P21 has the cleaner record: its mouse studies, including a 12 month Alzheimer model study, have no retractions. Dihexa's mechanism paper was retracted in 2025 and its main rat study carries an expression of concern.

Verified: Verified Sep 22, 2026
P21
Favored
Full P21 record

Which is better, P21 or Dihexa?

Both are graded animal only and both come from single research groups, so neither is a supported choice for human use. P21 wins on the quality of the animal record: normal mice showed better memory and dentate gyrus neurogenesis, and 12 months of oral dosing in 3xTg-AD mice reduced tau pathology and soluble amyloid beta, with no integrity flags. Dihexa's HGF/c-Met mechanism paper was retracted and its design paper is under an expression of concern. On regulation they are equivalent: neither can lawfully be compounded. [1] [2] [3] [4] [5]

How do P21 and Dihexa compare?

P21 and Dihexa compared by dimension
DimensionP21FavoredDihexa
What it is [1] [4]Adamantane modified tetrapeptide derived from the active region of ciliary neurotrophic factor (CNTF).Synthetic oligopeptide derived from angiotensin IV.
Proposed mechanism [1] [3] [6]CNTF mimetic that inhibits LIF signaling and raises BDNF, promoting neurogenesis and synaptic plasticity in mice.Reported to potentiate hepatocyte growth factor and c-Met signaling; the supporting paper was retracted in 2025.
Animal evidence [1] [2] [4]Better learning, memory, and neurogenesis in normal mice; 12 months of oral dosing in 3xTg-AD mice reduced tau hyperphosphorylation and soluble amyloid beta and rescued cognition.Reversed scopolamine induced water maze deficits and improved aged rat performance in one laboratory's studies.
Data integrity [3] [4] [6]No retractions or expressions of concern identified; single research group.Mechanism paper retracted (April 2025); design paper under a 2021 expression of concern; single research group.
Theoretical safety concern [6] [7]A growth factor mimetic could in theory influence tumor growth; not studied.Potentiating c-Met, an established oncogene, could promote tumor growth; no toxicology published.
Human evidence [4] [6]None. No trial registration, pharmacokinetic study, or safety report.None. No human study of any kind.
FDA and compounding status [5] [8]Never nominated for the 503A or 503B bulks lists and not on the Category 2 page; not compoundable.Nominated and placed in Category 2, then withdrawn; not on the bulks list and not reviewed by PCAC; not compoundable.
WADA status [9]Prohibited at all times under S0 (non-approved substances).Prohibited at all times under S0 (non-approved substances).

Evidence grade and regulatory status

Pulled from each peptide’s own record, so it stays in step with the peptide pages.

P21 and Dihexa: grade, status, and cost
AttributeP21Dihexa
ClassSynthetic adamantane-modified tetrapeptide derived from the active region of ciliary neurotrophic factor (CNTF)Synthetic angiotensin IV derived oligopeptide (hexanoyl capped Tyr-Ile with an aminohexanoic amide tail), hepatocyte growth factor/c-Met potentiator
What it isLab-made peptide mimicking part of CNTF, a protein that keeps nerve cells alive; mouse and rat memory and Alzheimer data; no human studies of any kind.Oral lab-made relative of the brain peptide angiotensin IV: rat memory data from one lab, a retracted mechanism paper, no human trials, no FDA approval.
EvidenceEvidence: Animal-only evidenceEvidence: Animal-only evidence
FDA statusRegulatory: UnscheduledRegulatory: Nomination withdrawn
CompoundingP21 is not an FDA approved drug and is not part of any approved drug. As of the last verification date it does not appear in any FDA 503A category or on the list of withdrawn nominations, and it is not on the 503A bulks list. It is therefore outside FDA's interim policy, and a 503A pharmacy has no federal basis to compound it from bulk. It is not eligible for 503B outsourcing.Dihexa has never been approved by FDA for any use. It was previously in 503A Category 2. FDA now lists dihexa acetate among nominations withdrawn by the nominators and notes that it has found no human exposure data. That places it in no 503A category and outside FDA's interim enforcement policy. FDA has said it will ask the Pharmacy Compounding Advisory Committee to consider dihexa acetate for the 503A bulks list at a meeting planned before the end of February 2027. As of the last verification date, no meeting date had been announced. Because it is not on that list, a 503A pharmacy has no federal basis to compound it, and no 503B pathway has been identified.
WADAWADA: WADA prohibitedWADA: WADA prohibited
RoutesOral in diet (mouse studies), Peripheral injection (mouse studies), Sold as oral capsules or injection by research chemical sellers (unapproved drugs when sold for human use)Oral (rat studies; sold as capsules or powder), Intraperitoneal injection (rat studies), Transdermal and subcutaneous products exist without absorption data
Typical costNot available through licensed channels. Research chemical sellers list it, but those products are unapproved drugs when sold for human use and are not verified for identity or purity.Not available through licensed channels. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity.
Last verified

Has P21 been tested directly against Dihexa?

No published trial has compared P21 and Dihexa directly. The dimensions above come from separate studies and labels, and cross-trial comparisons are less reliable than a direct trial.

What do P21 and Dihexa cost?

Typical cost of P21 and Dihexa
DimensionP21Dihexa
Typical costNot available through licensed channels. Research chemical sellers list it, but those products are unapproved drugs when sold for human use and are not verified for identity or purity.Not available through licensed channels. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity.
Price detailPrice index in progressPrice index in progress

Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.

What's actually offered, what that means for you, and what to check if you're going ahead anyway: see the P21 page and the Dihexa page.

Frequently asked questions

Is P21 or dihexa better for memory?

Neither has been tested in humans. In mice, P21 improved memory and neurogenesis and reduced Alzheimer type pathology over 12 months; dihexa improved rat water maze performance in studies whose mechanism paper was later retracted. Neither result can be assumed to apply to people. [1] [2] [3] [4]

Can either be prescribed or compounded?

No. P21 has never been nominated for the bulks lists, and dihexa's nomination was withdrawn without a bulks list recommendation, so neither has a lawful basis for 503A or 503B compounding. Research chemical products sold for human use are unapproved drugs. [5] [8] [10]

Is there any human safety data?

No. Neither has a published human study, and neither has a published formal animal toxicology study. Both have theoretical concerns tied to growth factor signaling. [6] [7]

Are they banned in sport?

Yes. Both are prohibited at all times under S0 of the WADA Prohibited List as non-approved substances. [9]

Conditions studied

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

  1. [1]Li B et al. Neurotrophic peptides incorporating adamantane improve learning and memory, promote neurogenesis and synaptic plasticity in mice. FEBS Lett 2010PubMed 20600002, 2010
  2. [2]Kazim SF et al. Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease. Neurobiol Dis 2014PubMed 25046994, 2014
  3. [3]Benoist CC et al. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system. J Pharmacol Exp Ther 2014 (retracted April 2025)PubMed 25187433, 2014
  4. [4]McCoy AT et al. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. J Pharmacol Exp Ther 2013 (expression of concern 2021)PubMed 23055539, 2013
  5. [5]FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2 list and withdrawn nominations, current as of April 22, 2026)FDA, 2026
  6. [6]Kazim SF, Iqbal K. Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's disease. Mol Neurodegener 2016PubMed 27400746, 2016
  7. [7]Wright JW, Harding JW. The brain hepatocyte growth factor/c-Met receptor system: a new target for the treatment of Alzheimer's disease. J Alzheimers Dis 2015 (review by the developers)PubMed 25649658, 2015
  8. [8]FDA: Compounding and the FDA, questions and answersFDA, 2026
  9. [9]WADA Prohibited List, section S0 non-approved substancesWADA, 2026
  10. [10]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style
PeptideAgent. (2026, September 22). P21 vs Dihexa: evidence, cost, and legality. https://peptideagent.ai/compare/p21-vs-dihexa
HTML link
<a href="https://peptideagent.ai/compare/p21-vs-dihexa">P21 vs Dihexa: evidence, cost, and legality</a>, PeptideAgent, updated September 22, 2026.